Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 4, 1997, Pages 1111-1117

  Holloway, Leah ^b   Kohlmeier, Lynn ^b   Kent, Kyla ^b   Marcus, Robert ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; DIPHENHYDRAMINE; ESTROGEN; HUMAN GROWTH HORMONE; OSTEOCALCIN; PLACEBO; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; SALCATONIN; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; EDEMA; ESTROGEN THERAPY; FEMALE; FEMUR; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANIMALS; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; CALCITONIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POSTMENOPAUSE; RECOMBINANT PROTEINS; SALMON;

EID: 0030906085     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.4.1111     Document Type: Article

References (26)

1. Rudman D. 1985 Growth hormone, body composition, and aging. J Am Geriatr Soc. 33:800-807.
2. Marcus R, Butterfield G, Holloway L, et al. 1990 Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab. 70:519-527.
3. Brixen K, Nielsen HK, Mosekilde L, Flyvbjerg A. 1990 A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Miner Res. 5:609-618.
4. Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R. 1994 Effect of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab. 79:470-479.
5. Stracke H, Schultz A, Moeller D, Rossol S, Schatz H. 1984 Effect of growth hormone on osteoblasts and demonstration of somatomedin C/IGF-I in bone organ culture. Acta Endocrinol (Copenh). 107:16-24.
6. 3 and activity on human osteoblast-like cells in short-term cultures. Bone. 11:81-86.
7. Barnard R, Ng KW, Martin TJ, Waters MJ. 1991 Growth hormone (GH) receptors in clonal osteoblast-like cells mediate a mitogenic response to GH. Endocrinology. 128:1459-1464.
8. Ernst M, Froesch ER. 1988 Growth hormone dependent stimulation of osteoblast-like cells in serum-free cultures via local synthesis of insulin-like growth factor I. Biochem Biophys Res Commun. 151:142-147.
9. Rudman D, Feller AG, Nagraj HS, et al. 1990 Effects of human growth hormone in men over 60 years old. N Engl J Med. 323:1-6.
10. Papadakis MA, Grady D, Black D, et al. 1996 Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med. 124:708-716.
11. Aloia JF, Vaswani A, Kapoor A, Yeh JK, Cohn SH. 1985 Treatment of osteoporosis with calcitonin, with, and without growth hormone. Metabolism. 34:124-129.
12. Aloia JF, Vaswani A, Meunier PJ, et al. 1987 Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin. Calcif Tissue Int. 40:253-259.
13. Ghiron L, Thompson JL, Holloway L, et al. 1995 Effects of recombinant insulin-like growth factor-I, and growth hormone on bone turnover in elderly women. J Bone Miner Res. 10:1844-1852.
14. Thompson JL, Butterfield GE, Marcus R, et al. 1995 The effects of recombinant human insulin-like growth factor-I, and growth hormone on body composition in elderly women. J Clin Endocrinol Metab. 80:1845-1852.
15. Melton III LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. 1993 Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 8:1227-1234.
16. The Writing Group for the PEPI Trial Investigators. 1996 Hormonal effects on bone mineral density in the spine, and hip: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 276:1389-1396.
17. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. 1980 Decreased risk of fractures of the hip, and lower forearm with postmenopausal use of estrogen. N Engl J Med. 303:1195-1198.
18. Watts NB, Harris ST, Genant HK, et al. 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 323:73-79.
19. Liberman UA, Weiss SR, Broll J, et al. 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 333:1437-1443.
20. Black D, Cummings SR, Karpf DB, et al. 1996 Alendronate reduces the risk of fractures in women with existing vertebral fractures: results of the Fracture Intervention Trial. Lancet. 348:1535-1541.
21. Marcus R. 1987 Normal and abnormal bone remodeling in man. Annu Rev Med. 38:129-141.
22. Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV. 1988 Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest. 82:1268-1274.
23. Riggs BL, Hodgson S, O'Fallon WM, et al. 1990 Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 322:802-809.
24. Kleerekoper M, Peterson EL, Nelson DA, et al. 1991 A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int. 1:155-161.
25. Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. 1995 Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med. 123:401-408.
26. Ebeling PR, Jones JD, O'Fallon WM, Janes CH, Riggs BL. 1993 Short-term effects of recombinant human insulin-like growth factor-I on bone turnover in normal women. J Clin Endocrinol Metab. 77:1384-1387.